These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 25824308)

  • 1. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
    J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
    Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
    Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
    Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
    Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
    Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolocumab: First Global Approval.
    Markham A
    Drugs; 2015 Sep; 75(13):1567-73. PubMed ID: 26323342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
    Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS;
    Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
    N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.